MACKAY MARTIN 4

What Happened

• Martin Mackay, a director of Charles River Laboratories (CRL), received two restricted stock unit (RSU) grants on 2026-05-08 totaling 2,845 shares. The grants were reported at $177.62 per share: 1,438 RSUs valued at $255,418 and 1,407 RSUs valued at $249,911, for a combined reported value of $505,329.
• These were awards (compensation) rather than open-market purchases or sales; one grant was explicitly made in lieu of director service fees for the term beginning May 5, 2026.

Key Details

• Transaction date: 2026-05-08; Form 4 filed: 2026-05-11 (timely filing).
• Price used for reporting: $177.62 per share.
• Total shares granted: 2,845 RSUs; total reported value: $505,329.
• Shares owned after transaction: not specified in the provided filing.
• Vesting: RSUs vest upon the earlier of May 8, 2027, or the business day prior to the company’s next annual meeting of shareholders (per footnotes). One grant was made in lieu of director fees.
• No 10b5-1 plan, cashless exercise, or tax-withholding sale noted in the provided details.

Context

• RSU grants are a form of compensation for directors and do not necessarily indicate a buy or sell signal about the company’s stock—rather, they align director pay with shareholder interests. The filing documents compensation-related awards and a standard vesting schedule.